^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Preclinical evaluation of SIM1803-1A, a small molecule Trk/ROS1 dual inhibitor for wild and mutate NTRK/ROS1 fusion solid malignancies.

Published date:
05/28/2020
Excerpt:
SIM1803-1A showed...high efficacy in the subcutaneous NSCLC LU-01-0414 SDC4-ROS1 PDX model with 60% and 74% TGI at 1 and 3 mg/kg (bid) dosing.
DOI:
10.1200/JCO.2020.38.15_suppl.e21663